Research

Market Views & Research

Macro analysis, investment theses, and market commentary from the Strand Global Macro research team.

Featured Analysis

Highlighted research from the Strand Global Macro team.

Latest Research

Boston Scientific Corporation  company logo
PDF

Boston Scientific Corporation

Bullish on Boston Scientific as the market underestimates the durability of its growth across cardiovascular device franchises and overstates the risk that recent legal, acquisition and product concerns will impair the broader earnings story. The thesis is that continued strength in high-growth areas such as electrophysiology and structural heart, combined with operating leverage and market expansion can sustain upside to expectations that the current valuation does not fully reflect.

Sky Reinecken|20 Apr 2026|
HealthcareMedTechCardiovascular
McCormick Overweight  company logo
PDF

McCormick Overweight

McCormick and Company is rated Overweight with a fair value of $67 and a target purchase price of $47 because the analysis predicts that temporary headwinds from tariffs and inflation will be resolved by organic growth and Mexico business synergies by the year 2027.

Hugo Raffard|26 Mar 2026|
Equities
Contributors:
Gabriel Zubiria
Nintendo company logo
PDF

Nintendo

Bullish on Nintendo as the market misprices cyclical hardware margin compression as structural deterioration, while underappreciating the durability of its first-party intellectual property and debt-free balance sheet. The thesis is that accelerating software mix shift, Switch 2 momentum, and an upcoming film release create a convergence of earnings tailwinds within a single reporting cycle that the current price does not reflect.

Jinwoo Jung|26 Mar 2026|
Equities
Keurig Dr Pepper company logo
PDF

Keurig Dr Pepper

Long thesis on Keurig Dr Pepper as the market appears to have overreacted to the JDE Peet’s deal, leaving shares well below a modelled fair value of about $42 versus roughly $28. The case rests on manageable post-deal leverage, beverage growth, margin improvement, and execution of synergies, with key risks from coffee costs, regulation, and weak coffee volumes.

Hugo Raffard|20 Mar 2026|
Equities